News - Page 2 of 6 - Sound Pharmaceuticals

Jun 25

Love0

Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere’s Disease clinical trial

By Jim News Short

SPI-1005 hits pre-specified endpoints resulting in a significant improvement in hearing loss of 65% and 95% relative to placebo

Mar 20

Love0

Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial

By Jim News Short

Jan 14

Love0

Sound Pharmaceuticals advances Phase 2 hearing loss clinical trial in Cystic Fibrosis

By Jim News Short

Oct 18

Love0

Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study

By Jim News Short

Nov 01

Love0

University of Oxford and Sound Pharmaceuticals begin Phase 2 clinical trial on novel treatment for bipolar disorder

By Jim News Short

Oct 03

Love0

Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Meniere’s Disease

By Jim News Short

Sep 29

Love0

Enrollment Underway in CF Clinical Trial for Ear Toxicity Caused by Antibiotics

By Jim News Short

Jun 29

Love0

Sound Pharmaceuticals completes enrollment on Meniere’s Disease clinical trial

By Jim News Short

Mar 20

Love0

Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use

By Jim News Short

Nov 01

Love0

Sound Pharmaceuticals announces two new executive hires to accelerate its Meniere’s drug development program

By Jim Home Page, Uncategorized

Seattle, WA

Sound Pharmaceuticals, a pioneer in the development of novel drug treatments for inner ear disease, announces the hiring of two senior executives. Paul Hoskins, Senior Director of Clinical Operations and G. Michael Wall, PhD, Senior Director of Pharmaceutical Development joined the company this past month. Read More

Previous 1 2 3 4 … 6 Next

All Rights Reserved, Sound Pharmaceuticals.